Fischer et al. revealed that the anti-PlGF antibody essentially blocks macrophage recruitment to orthotopic pancreatic tumors, reduces TAMs recruitment, as well as tumor VEGF-C levels, which, in turn, diminishes both lymphatic vessel density and lymph node metastasis [33]. This evidence concerns the gene VEGFC and neoplasm.